summari analyst day highlight
enhanc pipelin innov new product geograph
expans opportun expect acceler sale growth
continu margin expans overal
encourag cadenc new product geograph roll
come year manag financi target seem
reason even somewhat conserv although believ
conservat appropri given risk associ new
product approv launch continu signific
financi flexibl includ nearli estim cumul
free cash-flow unlev balanc sheet
see upsid bax long-term outlook via acquisit growth
asset net-net believ analyst meet yield major
surpris manag set bar appropri
outlook increas price target base
blend ev/ebitda dcf valuat methodolog
growth focus portfolio innov geograph
expans target revenu growth
includ headwind gener competit compris
organ growth new product
geograph expans new product geographi expect
help acceler pace sale growth
specif anticip ad risk-adjust revenu
new product geographi vast major
new opportun
medic deliveri
renal overal
expect outpac relev market growth busi
except compar analyst meet
market growth segment seem slightli lower figur
balanc sheet continu under-lev current
net cash balanc sheet coupl
cumul next five year unlev balanc
sheet compani signific financi flexibl invest
busi buy accret growth asset buy-back share
although compani see deal size current
market cap reason sens manag
continu prefer seri smaller deal instead larger
acquisit given typic challeng gener suffici
return integr larger transact manag note
import deal synergist current busi
gener double-digit intern rate return would accret
current growth outlook given organ pipelin believ
area like gener inject advanc surgeri remain
target inorgan growth
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
adjust spin-off baxalta
compani prioriti stock list
compani data secur llc estim reuter
continu previou page
outlook rais expect compani expect sale grow compound-annual-growth-rate
includ headwind cyclophosphamid brevibloc competit
expect sale compound-annual-growth-rate juli expect oper
margin prior expect midpoint new rang compani
continu work cost save initi expect gross margin cost control drive
continu margin expans tax rate manag expect rate approxim
guidanc expect gener profit higher
tax geographi like us overal see ep rang
juli analyst meet guidanc
assum signific contribut busi develop signific share repurchas
anticip margin higher figur
outlook impli steadi margin improv ep growth anticip
sale grow compound-annual-growth-rate growth expect acceler
growth current portfolio growth driven new product
launch geograph expans manag indic risk-adjust new product sale
oper margin expect continu increas averag
improv year manag expect nearli
margin improv driven higher gross margin improv mix contribut
higher margin new launch manufactur optim effort sg expect contribut
remain margin expans next year continu execut zero-
base budget program anticip ep impli compound-annual-growth-rate bottom-
line growth high-teen growth expect may prove conserv see
updat forecast forecast total revenu growth
oper margin ep estim bracket updat guidanc
model total revenu growth impli compound-annual-growth-rate
also slightli compani target busi area model bax
renal vs bax acut therapi vs bax estim oper
margin ep shi bax expect believ
bax long-term sale growth ep outlook reason achiev model
conserv due uncertainti associ new approvals/launch limit visibl
inject pipelin largest piec new product sale
medic deliveri three new pump come year forecast global
medic deliveri market grow estim market iv
therapi alreadi hold posit believ iv solut busi well
posit growth compani recent realloc unit ou suppli us
market profit market importantli compani plan new pump launch
next year believ could return infus system revenu growth solid growth
us compani launch latest spectrum iq pump drive addit share gain
track launch evo iq infus ou evo iq bax first new ou pump offer
mani year repres new market opportun bax ou infus system revenu
declin past coupl year due lack competit pump would expect
evo iq launch help busi regain share acceler growth
target introduct new pump platform incorpor among
thing modular setup syring pump still leverag drug librari recal
launch sigma spectrum pump us us infus system revenu acceler
double-digit growth subsequ two year new product increas capac
iv solut target above-market growth anticip
pharmaceut dozen new molecul launch plan estim current
compet segment broader global injectable/compounding/inh anesthesia
market broader market expect grow bax current address
market expect grow due declin inhal anesthesia market slower
growth drug compound anticip launch nearli new molecul via clari
sinopharm next year expect address market doubl
competit inject portfolio molecul focus therapeut
area addit new molecul expect leverag hospit channel strength
special manufactur capabl drug deliveri expertis drive growth busi
target inject growth line overal market repres
new product sale exclud anticip headwind cyclophosphamid
brevibloc competit manag estim inject busi grow
double-digit contempl potenti gener supran competit next
year believ manufactur distribut challeng like limit impact
competit addit compani target potenti earli entri opportun
brand sale face us patent expir next year evalu biosimilar prospect
oncolog support care see gener inject busi one import
driver top-lin growth margin expans
renal new technolog geographi reshap busi estim renal
care market grow see growth opportun hd hemodialysi
pd periton dialysi market compris hd pd bax renal
revenu mix opposit us recent complet patient enrol studi
theranova dialyz anticip fda file year-end suggest commerci roll
hdx expand hd theranova help expand rang toxin remov dialysi
retain essenti protein use standard equip ou launch kaguya
autom pd japan anticip theranova launch china kaguya specif
design japanes market touch-fre connect id well monitor via
sharesourc japanes home therapi market significantli penetr vs
global acknowledg previou lack product specif address need
addit theranova kaguya remain track start trial poc point care
home solut system later commerci time-frame success poc
alter home dialysi significantli reduc volum solut requir simplifi
solut product enabl system prescript deliveri cycl new product plu ou
expans expect drive bulk anticip new product sale
estim help deliv above-market growth emerg
market em focu analyst meet em highlight import growth driver
renal busi afford easier use solut
advanc surgeri refresh portfolio forecast advanc surgeri market
grow major market compris hemostat sealant
player current manag note portfolio stale number
gap compani start address reinvigor pipelin recent
recothrom/preveleak acquisit target growth busi driven
new product launch plan expans japanes chins market
acut therapi small fast grow market forecast global market grow
bax current acut therapi revenu crrt continu renal
replac therapi although compani target doubl revenu organ support therapi
next year target growth acut revenu new launch
like prismax geograph expans market like japan expand global salesforc
improv reimburs crrt us
nutrit acceler launch cadenc forecast global parenter nutrit market
grow compani hope deliv above-market growth
acceler cadenc new launch expand reach global manag
highlight import market develop especi build evid educ
benefit nutrit new launch high protein product innov readi infus
packag help meet patient need potenti streamlin process hospit
guidancesegmentscurr mktoutlookestmkt shrcurrent analyst dayinfus solut current address potenti address sealant surgeri renal replac therapi support therapi low-effici dialysi sled intermitt hd dialysi analyst day secur llc estimatesnot end-market growth rate calcul base weight averag end-market sale analyst cagrcurr growthend-market sale analyst cagrcor growthcor return capitalmaintain manag differentlystrateg betsacut therapi crrt advanc surgerygener inject drugsclin nutritioninh anesthesiaiv solut select geographi iv pump setsperiton dialysisbiopharma solutionscompoundingelastomericsin-cent hemodialysisdisrupt renal modelscrit extracorpor therapiesspeci monitoring/ pivadigit healthinfect control compani report secur llc baxter intern inc
sale growthreport sale growthfxotherren oper expenseoth incomeadj ebitda tax countop compani report factset secur llc estim underli growth exclud cyclophosphamid competit exit low-margin busi exclud impact clari acquisit exit low-margin em busi includ clari acquisit exit low-margin em busi includ cyclo clari acquisit compound-annual-growth-rate base year compound-annual-growth-rate base guidanc medic technolog
price target
price target base equal weight ev/ebtida dcf price-to-earnings risk
thesi includ unexpect competit headwind could slow restructur effort signific delay new
believ acceler sale growth expand oper margin consist deliv
reliabl low double-digit ep growth strong balanc sheet could enhanc long-term growth
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
statement fy end dec million except per share revenu report structur -- hospit product gross gross tsa transit svc agreement sg total oper oper net interest incom expens incom expens total non-op incom expens pre-tax incom tax expens net adjust share outstand marginsgross ex-msa changetot share compani report secur llc estim
